Picture loading failed.

Pre-Made Muromonab biosimilar, Whole mAb, Anti-CD3E Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Muromonab-CD3 (trade name Orthoclone OKT3, marketed by Janssen-Cilag) is an immunosuppressant drug given to reduce acute rejection in patients with organ transplants. It is a monoclonal antibody targeted at the CD3 receptor, a membrane protein on the surface of T cells. It was the first monoclonal antibody to be approved for clinical use in humans.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-360-1mg 1mg 3090
GMP-Bios-ab-360-10mg 10mg Inquiry
GMP-Bios-ab-360-100mg 100mg Inquiry
GMP-Bios-ab-360-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Pre-Made Muromonab biosimilar, Whole mAb, Anti-CD3E Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon therapeutic antibody
INN Name Muromonab
TargetCD3E
FormatWhole mAb
Derivation
Species ReactivityHuman
CH1 IsotypeIgG2a
VD LCKappa
Highest_Clin_Trial (Jan '20)Approved
Est. StatusDiscontinued
100% SI Structure1sy6:HL
99% SI StructureNone
95-98% SI StructureNone
Year Proposed1988
Year Recommended1989
CompaniesCancer Research UK;Ortho-McNeil;XOMA
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedDiabetes mellitus;Graft-versus-host disease;Renal transplant rejection;Rheumatoid arthritis
Development Techna